Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.

Arrakis Therapeutics Inc. is in the middle of a big pivot from building its platform for the discovery of small molecules that target RNA to generating a pipeline of drug candidates – and now it has $75m in Series B venture capital funding to expand its compound library and advance its first programs into the clinic.

The Waltham, Mass.-based company also now has a permanent CEO since Michael Gilman, who has been splitting his time between...